Therapeutic Areas

Are you developing any of the following?

• Small molecules
• Biologics
• Peptides
• Cell and gene therapies
• Antibody based modalities
• Next-generation therapeutic constructs

If yes, our multidisciplinary teams will provide you with end-to-end support anchored in high-quality, decision-driving data.

How to solve your therapeutic research challenges

Improve translatability: Building disease-relevant, human-centric models and designing robust assays to enhance the predictive value of preclinical studies.

Reduce development risk: High-quality data supported by expert interpretation enabling confident go/no-go decisions at every stage.

Accelerate timelines, without compromise: Flexible team structures, efficient custom workflows and scientific expertise allow projects to progress rapidly without sacrificing quality.

Tailor solutions to your biology and modality: Whether developing small molecules, biologics, peptides, oligonucleotides, cell / gene therapies or antibody constructs, we adapt our models and assays to match your modality and mechanistic goals.

Scientific expertise across key therapeutic areas

Despite significant advances in molecular and cellular biology, the processes driving many diseases remain elusive. Our scientists bring deep, cross-disciplinary insight to help you unravel disease mechanisms, identify dominant pathways and generate data that guides therapeutic strategy with confidence.

Every assay, model and data package is tailored to your biology, ensuring your project obtains results that directly answer your scientific questions.

Neuroscience and CNS disorders

We support programs addressing neurodegeneration, neuroinflammation, synaptic function and cognitive decline. Using primary and iPS-derived cells and disease-relevant CNS models, delivering translational insights that help you evaluate mechanism of action, pathway engagement and therapeutic potential.

• Advanced 3D CNS models, including organotypic brain slices
• iPSC derived microglia, astrocytes, neurons, and OPC platforms
• Primary CNS and glial cell systems
• Mechanistic neuroinflammation, myelin biology, and neuronal biology assays
• Neurodevelopment and neurotoxicity screening using CNS relevant cell lines

Immunology

While the underlying cause of disease is often unclear, a dysfunctional immune response often drives illness. Whether it is the absence of an effective response or excessive cell mediated immunity, our immunologists have decades of experience in oncology, autoimmunity, inflammatory diseases and infection.

To help you confidently evaluate the efficacy of your drug candidate, we offer a broad suite of validated and customizable primary immune cell assays, with bespoke solutions designed around your programs toughest scientific questions.

• Innate and adaptive immune activation assays
• Cytokine and chemokine profiling platforms
• Primary human immune cell isolation and functional analysis
• Mechanistic inflammation and autoimmunity models
• Immune cell phenotyping and flow cytometry panels

Immuno-oncology

Aquila BioMedical, now Concept Life Sciences, was one of the earliest UK-based CROs focused on immuno‑oncology. Building on that legacy, we now have over a decade of experience at the forefront of pre clinical testing for cancer therapeutics.

We combine specialist expertise in:

• Tumor-immune cell interaction models
• Immune checkpoint pathway assays
• Primary immune cell systems
• Tumor microenvironment and 3D modeling

allowing you to evaluate potency, signaling pathways and therapeutic activity with high translational relevance.

Oncology

Build confidence in your candidates’ progression using our oncology capabilities to provide the mechanistic clarity essential for next-stage development.

Concept Life Sciences supports oncology programs through:

• Cell viability, proliferation, and apoptosis assay platforms
• Reporter based functional assays tumor microenvironment and mechanistic studies (2D and 3D)
• In vitro oncology models
• In vivo (via partnerships) and ex vivo support
• Phenotypic and biomarker analysis
• Spatial biology

Fibrosis

Characterize therapeutic impacts in fibrotic disease and related metabolic pathways, providing actionable insights to guide your drug development decisions with:

• Mesenchymal cell activation and differentiation assays.
• Collagen production, secretion, and ECM remodeling platforms.
• Epithelial–mesenchymal transition (EMT) and fibroblast crosstalk models.
• Macrophage differentiation and pro fibrotic polarization assays.
• Mechanistic in vitro models of tissue fibrosis across organ systems.

Integrated drug discovery development services

Drug discovery often suffers from fragmentation when biology, chemistry, ADMET/DMPK and toxicology are distributed across multiple vendors. Concept Life Sciences eliminates this, with a fully integrated platform that enables smoother workflows, faster timelines and cohesive data packages aligned with your therapeutic goals.

Our integrated drug discovery services bring together:

Discovery biology and mechanism-of-action studies - Custom in vitro models, disease-relevant systems, phenotypic assays, pathway interrogation.

Medicinal and synthetic chemistry - Optimization of potency, selectivity and developability using advanced chemistry workflows.

ADMET and DMPK, including in vivo PK - Integrated ADMET profiling, PK studies, bioanalysis and translational modelling.

Bioanalysis and analytical sciences - Robust quantitative analysis to support PK, toxicology and regulatory submissions.

Disease-relevant in vitro and in vivo toxicology - Early safety identification and risk mitigation using industry-standard and bespoke models

Project management and strategic scientific guidance - End-to-end project leadership ensuring timelines, data quality and scientific continuity.

This integration reduces delays, improves communication and results in cohesive, decision-ready data packages.

Why partner with Concept Life Sciences?

Scientific depth across multiple disease areas - Our biologists, chemists, pharmacologists and immunologists work collaboratively to deliver cohesive therapeutic insight.

Custom assay design and model development - Your program receives bespoke workflows shaped around specific research challenges not pre-defined templates.

Decision-driving data packages - We provide clear, contextual interpretation that guides next steps, supports regulatory documentation and de-risks therapeutic progression.

Flexible, integrated research capabilities - With biology, chemistry, ADMET, DMPK, toxicology and analytical services under one roof, we reduce operational delays and enhance scientific continuity.

Experience across modalities - We support small molecules, biologics, peptides, oligonucleotides, cell and gene therapies, antibody constructs and beyond.

Start your therapeutic discovery program

Whether you are targeting oncology, immunology, neuroscience, immuno-oncology, liver disease or emerging therapeutic areas, our experts are ready to help you build a robust, translationally meaningful discovery pathway.

Speak with our scientists today and discover how we can accelerate your therapeutic development.

Contact us today